No Data
LIR Life Sciences Corp. Announces Agreement With Resilience BioSciences Inc.
LIR Life Sciences Commences Project Phase 2 Peptide Design Program With Neuland Laboratories
LIR Life Sciences Reports Positive Interim Preclinical Results From Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules
LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform